Following the CABRI1 and ARTS2 trials on multivessel disease, a challenging new trial was proposed to surgeons, namely the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial, sponsored by Boston Scientific as an IDE FDA trial on the use of the TAXUSTM stent (Boston Scientific, Marlborough, MA, USA) in three-vessel disease and left main. Actually, the left main component of the trial was a proposal made by Marie-Claude Morice and Antonio Colombo.
No takes yet. Share an insight, caveat, or question.
Serruys et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: